1422269-30-4 ((S)-3-(1H-吲哚-3-基)-N-((1-(4-甲氧基苯基)环己基)甲基)-2-(3-(4-硝基苯基)脲基)丙酰胺,ML-18)

ML-18;化合物ML 18;ML-18游离态;(S)-3-(1H-吲哚-3-基)-N-((1-(4-甲氧基苯基)环己基)甲基)-2-(3-(4-硝基苯基)脲基)丙酰胺;

ML-18;ML18;ML 18;(S)-3-(1H-indol-3-yl)-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)-2-(3-(4-nitrophenyl)ureido)propanamide;GTPL8505;(2S)-3-(1H-indol-3-yl)-N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-2-[(4-nitrophenyl)carbamoylamino]propanamide;XGC26930;N17021;Q27086987;(?S)-N-[[1-(4-Methoxyphenyl)cyclohexyl]methyl-?-[[[(4-nitrophenyl)amino]carbonyl]amino]-1H-indole-3-propanamide;(2S)-3-(1H-indol-3-yl)-N-{[1-(4-methoxyphenyl)cyclohexyl]met;CID 91827363;BRS-3 antagonist;1422269-30-4;ML18, >98%;(2S)-3-(1H-INDOL-3-YL)-N-{[1-(4-METHOXYPHENYL)CYCLOHEXYL]METHYL}-2-{[(4-NITROPHENYL)CARBAMOYL]AMINO}PROPANAMIDE;Bombesin Receptor,ML-18,ML 18,inhibit,Inhibitor,ML18;ML-18?;DA-65518;AKOS027470221;GLXC-10307;(2S)-3-(1H-indol-3-yl)-N-((1-(4-methoxyphenyl)cyclohexyl)methyl)-2-(((4-nitrophenyl)carbamoyl)amino)propanamide;BS-15094;HY-101844;9a(S)-8-(3,5-Dichloro-2-dimethylamino-benzyl)-6(S)-(4-hydroxy-benzyl)-2-methyl-4,7-dioxo-hexahydro-pyrazino[2,1-c][1,2,4]triazine-1-carboxylic acid 2,3-dimethoxy-benzylamide;CS-6869;

MFCD30182327

JOKVJNCYOSFDGC-LJAQVGFWSA-N

1S/C32H35N5O5/c1-42-26-15-9-23(10-16-26)32(17-5-2-6-18-32)21-34-30(38)29(19-22-20-33-28-8-4-3-7-27(22)28)36-31(39)35-24-11-13-25(14-12-24)37(40)41/h3-4,7-16,20,29,33H,2,5-6,17-19,21H2,1H3,(H,34,38)(H2,35,36,39)/t29-/m0/s1

O=C([C@]([H])(C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)N([H])C(N([H])C1C([H])=C([H])C(=C([H])C=1[H])[N+](=O)[O-])=O)N([H])C([H])([H])C1(C2C([H])=C([H])C(=C([H])C=2[H])OC([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]